NuVasive receives FDA 510(k) clearance for limb lengthening system in pediatric patients

Fact checked byGina Brockenbrough, MA

Key takeaways:

NuVasive received FDA clearance of its limb lengthening solution to include pediatric patients.
Precice uses magnetically adjustable technology to lengthen implants in patients with limb length discrepancy.

NuVasive Inc. has announced FDA 510(k) clearance of its Precice all-internal limb lengthening solution to include pediatric patients, according to a press release.

Precice utilizes magnetically adjustable technology and an external remote to lengthen implants in patients with limb length discrepancy (LLD).

Generic FDA News infographic — NuVasive received FDA clearance of its limb lengthening solution to include pediatric patients, according to a press release.

“Everyone faced with LLD, especially pediatric patients, should have access to a non-invasive limb lengthening solution,” Pete Ligotti, leader of NuVasive Specialized Orthopedics, said in the release. “Backed by more than 100 peer-reviewed studies, the difference with Precice is that it accommodates the changing clinical needs of patients as they heal, grow and age, reducing the need for further surgeries throughout treatment,” Ligotti added.

Published by:

Sources/Disclosures

Collapse

Source:

Press Release

Read more

NuVasive receives FDA 510(k) clearance for limb lengthening system in pediatric patients

Key takeaways:

Related Content